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48.7% of the males and 52.0% of the females (p = 0.29)
were prescribed drug therapy within a year of diagnosis.
Median time to treatment was 436 (95% Cd, 289, 774)
and 318 (95% c.l. 176,518) days for men and women,
respectively.
CONCLUSIONS: In terms of both rate of drug therapy
initiation and time to treatment for lipid disorders, our
study showed no statistically significant difference be-
tween men and women.
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The "statin" market is highly competitive, with primary dif-
ferences being lipid-lowering ability and acquisition cost.
Health care decision makers must be able to demonstrate
and compare the clinical and economic value of each statin.
To date, the best available data for such comparisons come
from the long-term studies 4S, CARE, and WOSCOPS.
OBJECTIVE: Lipobay, a potent new statin, was recently
introduced in Europe and will be introduced in the
United States as Baycol this year. Our objective was to
model the clinical and economic results of 4S to compare
the cost-efficiency of Lipobay to other statins.
METHODS: Our research was based on the following
assumptions: lipid-lowering ability and acquisition cost
are the only distinctions among statins; a positive linear
relationship exists between reduced lipids and reduced
cardiovascular costs; all statins, based on efficacy and
cost, can be incorporated into this relationship. Using
these assumptions, we extracted numeric data points for
cardiac hospitalization cost in 4S and developed a linear
equation, incorporating efficacy and drug cost, to esti-
mate total cost for each statin. Our cost-efficiency mea-
surement consisted of an index calculated by dividing es-
timated annual per patient total cost or drug cost in
Deutchmarks by unit reduction in LDL. This measure-
ment is interpreted as the cost per unit reduction in LDL.
Drugs whose total and drug cost indices had negative or
zero slopes when graphed and low indices were consid-
ered cost-efficient.
RESULTS: Lipobay presented a negative slope for the to-
tal cost indices and a zero slope for drug cost indices.
When comparing actual cost indices for all drugs, Lipobay
was generally within mid-range (total cost: DM98-
DM149; drug cost: DMI4).
CONCLUSION: Lipobay is cost-efficient when com-
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Lipid-lowering (LL) drugs decrease morbidity and mor-
tality due to coronary heart disease (CHD). Among CHD
patients, some LL drugs also decrease overall mortality.
To realize the therapeutic benefits, LLdrugs must be used
for at least two years. A previous study in Saskatchewan
showed that patient adherence to LLdrugs is poor.
OBJECTIVES: The objective of this study is to quantify
the direct costs of non-adherence to LL drug therapy. The
first phase will focus on pharmaceutical costs. Subse-
quent analyses will include physician services and hospi-
talization costs.
METHODS: The government of Saskatchewan maintains
comprehensive, linkable databases on health services pro-
vided to the population of approximately one million res-
idents. Eligible beneficiaries with one or more outpatient
prescriptions for LL drugs between 1989 and 1996 were
identified. Exposure time was calculated for each subject.
Cost analyses were conducted from the societal perspec-
tive.
RESULTS: LL drugs were commonly used in Saskatchewan
during the study period: 629,728 prescriptions for LL
drugs were dispensed to 32,758 people (approximately
3% of the population). Statins were the most widely used
LL drugs, followed by gemfibrozil and cholestyramine.
On average, subjects were exposed to LL drugs for 1.7
years. Only 35% of LL drug users were exposed for two
years or longer. The total cost of LL prescriptions during
the study period was $44.6 million CAN. However, $6.9
million (15%) of these costs were for prescriptions dis-
pensed to people who used LL drugs for less than two
years.
DISCUSSION: Poor patient adherence to LL drugs re-
sults in substantial wastage of pharmaceutical expendi-
tures. Future analyses will focus on outcomes associated
with non-adherence and their impact on overall physician
service, hospitalization and drug costs.
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There are currently rapid developments in our ability to
offer effective preventive and therapeutic interventions
for sufferers of stroke. Concurrent pressure on national
and local health care budgets demands that new interven-
tions be evaluated for their cost-effectiveness before their
widespread implementation. Clinical trials are of rela-
Abstracts
tively short duration and therefore cannot directly mea-
sure the long-term impact of therapies.
OBJECTIVE: To develop a flexible and comprehensive
tool to assist rapid outcome evaluation of potential inter-
ventions in stroke care in four countries: France, Ger-
many, UK, US.
METHODS: Decision-analytic software was used to con-
struct a Stroke Outcome Model, which consists of 4 inter-
related modules: (1) primary prevention; (2) "bridge" to
acute care; (3) acute care (ischaemic stroke only); and (4)
long-term care/prevention of recurrence in stroke survi-
vors. Stroke prevention was represented by Markov state
transition processes, states being defined in terms of use of
therapy, disability and occurrence of (further) stroke. Data
sources included clinical trials and meta-analyses, and pro-
spective cohorts: Framingham study, Oxford Community
Stroke Project and North Manhattan Stroke Study. Re-
source use data were obtained from published sources,
supplemented by in-country panels of clinical experts, and
unit costs from relevant national sources.
RESULTS/DISCUSSION: The modelling approach has
enabled the long-term consequences of acute or preven-
tive therapy to be evaluated. Analyses have examined the
cost-effectiveness of: antiplatelets in prevention of stroke
recurrence; thrombolytic therapy in acute stroke; and
stroke units. Results were sensitive to the duration of fol-
low-up and the cost perspective chosen, in particular
whether long-term care costs were included. The model
enables users to explore issues such as the choice of effec-
tiveness parameter or background event risks, and how
risks are projected beyond the follow-up periods reported
in trials or prospective studies. More data are required on
long-term care, disability and quality of life/utility, and
adjusted risks for (first) stroke.
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ECONOMIC EVALUATION OF TORASIMIDE IN
CONGESTIVE HEART FAILURE IN GERMANY
Spannheimer A', Goertz N
'Kendle/gmi, Munich, Germany: 2Boehringer Mannheim,
Mannheim, Germany
Studies with classical clinical endpoints indicated compa-
rable efficacy and tolerability of the two loop diuretics to-
rasemide and furosemide in congestive heart failure
(CHF). However, differences in the pharmacological pro-
files suggested potentially different quality of disease con-
trol under real life conditions.
OBJECTIVE: The present study aimed at collecting data
in a naturalistic setting and comparing overall cost and
cost-effectiveness of torasemide and furosemide.
METHODS: Data on the course of the disease and on re-
lated resource utilization were collected retrospectively
from a one-year treatment period of 200 torasernide-
treated and 200 furosemide-treated patients. High com-
parability of the two patient groups was achieved by us-
ing the matched-pair method with nine demographic and
medical matching criteria.
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RESULTS: Disease control was better in the torasemide
patients, as reflected by fewer hospital days due to CHF
(324 vs. 62) and more patients with improvement of
NYHA class (torasemide: 38.0% [31.25%-45.11 %]; fu-
rosemide: 24.5% [18.71 %-31.06%]) during the observa-
tion period. Comparing overall cost from the statutory
health insurance's perspective, torasemide treatment is
less costly by 361 DEM per patient and year (1502 vs.
1863 DEM). Moreover, torasemide is clearly more cost-
effective: The cost per patient with improved NYHA
class is 3954 DEM for torasemide versus 7605 DEM for
furosemide. Analyses from the societal perspective
yielded similar results.
CONCLUSIONS: The data reveal substantial improvement
of disease control and reduction of treatment cost with to-
rasemide compared to furosemide. Furthermore, this study
highlights the value of collecting naturalistic data from bal-
anced populations to improve our understanding of drug ef-
fects on disease courses and health care cost.
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Since noncompliance is a major factor in the outcomes of
drug therapy for chronic conditions like hypertension, im-
proving compliance improves the outcomes of therapy. Re-
search with hypertensive patients has found more than
50% are noncompliant. Adherence to a medication regi-
men requires patients to change their behavior. Research
on a range of behaviors from smoking cessation to adopt-
ing an exercise program has found behavior change is a
process and individuals have different readiness to change.
OBJECTIVE: Examine how readiness to comply, pro-
cesses of change, temptations to be noncompliant, and
patients' views of the pros and cons of compliance are re-
lated to self-reported compliance.
METHODS: Several compliance measures, including a
readiness to comply scale, a pros and cons scale, a pro-
cesses scale, and a temptation to skip medication scale
were administered to 731 hypertensive patients, who also
reported their compliance in the last four weeks.
RESULTS: Readiness to comply was highly related to re-
ported compliance (contingency coefficient = .72, p <
.0001). As readiness to comply increased, overall level of
temptations decreased and patients rated the positive as-
pects of compliance or the pros higher and the negatives
or cons lower and used different processes of change.
CONCLUSIONS: Behavior change compliance measures
are related to self-reported compliance. Utilizing these
measures will improve assessment of an individual's
readiness to comply and permit creation of customized
interventions for individual patients.
